These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 9391781)
1. A high serum concentration of interleukin-6 is predictive of relapse in quiescent Crohn's disease. Louis E; Belaiche J; van Kemseke C; Franchimont D; de Groote D; Gueenen V; Mary JY Eur J Gastroenterol Hepatol; 1997 Oct; 9(10):939-44. PubMed ID: 9391781 [TBL] [Abstract][Full Text] [Related]
2. Soluble interleukin-2 receptor in Crohn's disease. Assessment of disease activity and prediction of relapse. Louis E; Belaiche J; Van Kemseke C; Schaaf N; Mahieu P; Mary JY Dig Dis Sci; 1995 Aug; 40(8):1750-6. PubMed ID: 7648975 [TBL] [Abstract][Full Text] [Related]
3. Frequently relapsing Crohn's disease is characterized by persistent elevation in interleukin-6 and soluble interleukin-2 receptor serum levels during remission. Van Kemseke C; Belaiche J; Louis E Int J Colorectal Dis; 2000 Aug; 15(4):206-10. PubMed ID: 11008719 [TBL] [Abstract][Full Text] [Related]
4. Oral 4-aminosalicylic acid versus 5-aminosalicylic acid slow release tablets. Double blind, controlled pilot study in the maintenance treatment of Crohn's ileocolitis. Schreiber S; Howaldt S; Raedler A Gut; 1994 Aug; 35(8):1081-5. PubMed ID: 7926910 [TBL] [Abstract][Full Text] [Related]
6. Tumour necrosis factor alpha and interleukin 1beta in relapse of Crohn's disease. Schreiber S; Nikolaus S; Hampe J; Hämling J; Koop I; Groessner B; Lochs H; Raedler A Lancet; 1999 Feb; 353(9151):459-61. PubMed ID: 9989717 [TBL] [Abstract][Full Text] [Related]
7. Elevation of serum interleukin-6 but not serum-soluble interleukin-2 receptor in children with Crohn's disease. Bross DA; Leichtner AM; Zurakowski D; Law T; Bousvaros A J Pediatr Gastroenterol Nutr; 1996 Aug; 23(2):164-71. PubMed ID: 8856584 [TBL] [Abstract][Full Text] [Related]
8. T-cell activation in Crohn's disease. Increased levels of soluble interleukin-2 receptor in serum and in supernatants of stimulated peripheral blood mononuclear cells. Mueller C; Knoflach P; Zielinski CC Gastroenterology; 1990 Mar; 98(3):639-46. PubMed ID: 2298368 [TBL] [Abstract][Full Text] [Related]
9. Serum levels of tumor necrosis factor-alpha (TNF-alpha), interleukin 6 (IL-6), and their soluble receptors in coal workers' pneumoconiosis. Zhai R; Liu G; Ge X; Bao W; Wu C; Yang C; Liang D Respir Med; 2002 Oct; 96(10):829-34. PubMed ID: 12412984 [TBL] [Abstract][Full Text] [Related]
10. Serum calprotectin as a biomarker for Crohn's disease. Meuwis MA; Vernier-Massouille G; Grimaud JC; Bouhnik Y; Laharie D; Piver E; Seidel L; Colombel JF; Louis E; J Crohns Colitis; 2013 Dec; 7(12):e678-83. PubMed ID: 23845231 [TBL] [Abstract][Full Text] [Related]
11. Assessing disease activity in Crohn's disease--are we there yet? Eliakim R; Rachmilewitz D Eur J Gastroenterol Hepatol; 1997 Oct; 9(10):929-30. PubMed ID: 9391778 [TBL] [Abstract][Full Text] [Related]
12. Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prospective study. Kallel L; Ayadi I; Matri S; Fekih M; Mahmoud NB; Feki M; Karoui S; Zouari B; Boubaker J; Kaabachi N; Filali A Eur J Gastroenterol Hepatol; 2010 Mar; 22(3):340-5. PubMed ID: 19581809 [TBL] [Abstract][Full Text] [Related]
13. Intestinal permeability test as a predictor of clinical course in Crohn's disease. D'Incà R; Di Leo V; Corrao G; Martines D; D'Odorico A; Mestriner C; Venturi C; Longo G; Sturniolo GC Am J Gastroenterol; 1999 Oct; 94(10):2956-60. PubMed ID: 10520851 [TBL] [Abstract][Full Text] [Related]
14. Gut mucosal secretion of interleukin 1beta and interleukin-8 predicts relapse in clinically inactive Crohn's disease. Arnott ID; Drummond HE; Ghosh S Dig Dis Sci; 2001 Feb; 46(2):402-9. PubMed ID: 11281191 [TBL] [Abstract][Full Text] [Related]
15. Cytokine network in rectal mucosa in perianal Crohn's disease: relations with inflammatory parameters and need for surgery. Ruffolo C; Scarpa M; Faggian D; Pozza A; Navaglia F; D'Incà R; Hoxha P; Romanato G; Polese L; Sturniolo GC; Plebani M; D'Amico DF; Angriman I Inflamm Bowel Dis; 2008 Oct; 14(10):1406-12. PubMed ID: 18452203 [TBL] [Abstract][Full Text] [Related]
16. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease. Martínez-Borra J; López-Larrea C; González S; Fuentes D; Dieguez A; Deschamps EM; Pérez-Pariente JM; López-Vázquez A; de Francisco R; Rodrigo L Am J Gastroenterol; 2002 Sep; 97(9):2350-6. PubMed ID: 12358255 [TBL] [Abstract][Full Text] [Related]
19. Decreased corticosensitivity in quiescent Crohn's disease: an ex vivo study using whole blood cell cultures. Franchimont D; Louis E; Dupont P; Vrindts-Gevaert Y; Dewe W; Chrousos G; Geenen V; Belaiche J Dig Dis Sci; 1999 Jun; 44(6):1208-15. PubMed ID: 10389698 [TBL] [Abstract][Full Text] [Related]
20. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives. Cellier C; Sahmoud T; Froguel E; Adenis A; Belaiche J; Bretagne JF; Florent C; Bouvry M; Mary JY; Modigliani R Gut; 1994 Feb; 35(2):231-5. PubMed ID: 7508411 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]